News from k-v pharmaceutical company A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NYSE:KV.B,NYSE:KV.A)

Feb 08, 2016, 08:30 ET

Aoxing Pharmaceuticals Q2 Revenue Up 27%; Net Income $2.1 Million, Up 265%

 Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced that for the second quarter of fiscal year 2016, ended December 31, 2015,...

Feb 03, 2016, 20:36 ET

FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD)

 Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the U.S. Food and Drug Administration's...

Feb 01, 2016, 08:30 ET

Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer

 Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development,...

Jan 27, 2016, 08:00 ET

Aprecia Pharmaceuticals Set to Advance 3D Printed Drug Pipeline with Completion of $35 Million Financing Led by Deerfield Management

Aprecia Pharmaceuticals Company, Inc., an emerging pharmaceutical company specializing in three-dimensionally printed (3DP) prescription medicine,...

Dec 10, 2015, 08:30 ET

Aoxing Pharma Selected to Supply Zhongtongan to the Insurance System for the City of Shanghai

 Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development,...

Dec 04, 2015, 08:30 ET

Aoxing Pharma Announces Opening Of Government Funded Drug Research Center

 Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development,...

Dec 04, 2015, 08:00 ET

Aoxing Pharma Announces Resignation of CFO

 Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development,...

Nov 18, 2015, 17:05 ET
About  Respiratory Syncytial Virus (PRNewsFoto/Alios BioPharma, Inc)

New Data Published in the New England Journal of Medicine Shows Potential of Compound to Fight RSV Infection

- ALS-008176 now being evaluated in RSV-infected infants - Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that...

Nov 13, 2015, 10:18 ET

Takeda Receives Back-to-Back Recognition, Named a 2015 Top Chicago Workplace

 Takeda announced today that the Chicago Tribune named Takeda's Deerfield campus among Chicago's Top 100 Workplaces in 2015. This is the fourth...

Nov 13, 2015, 08:30 ET

Aoxing Pharmaceuticals Q1 Revenue Up 92 Percent; Net Income Of $1.35 Million

 Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced that, for the first quarter of fiscal 2016 ended September 30, 2015, the...

Nov 09, 2015, 10:45 ET
Eli Lilly and Company logo

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

 New sub-analysis data presented today showed the reduction in risk for hospitalization for heart failure or cardiovascular death with...

Nov 06, 2015, 08:00 ET
Eli Lilly and Company logo.

EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced that top-line renal results from the...

Oct 02, 2015, 10:57 ET

Takeda Celebrates Fifth Annual Takeda Cares Day by Expanding Nationwide and Raising More Than $250,000 for Chicagoland Nonprofits

 For the fifth consecutive year, Takeda Pharmaceutical employees are gathering at the company's U.S. headquarters in Deerfield to raise money...

Sep 17, 2015, 11:46 ET

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company's (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the...

Aug 20, 2015, 07:30 ET
Eli Lilly and Company logo.

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a...

Aug 10, 2015, 18:36 ET

FDA Accepts a Supplemental New Drug Application for Review of Brintellix® (vortioxetine) Clinical Trial Data That Assessed Cognitive Function in Patients with Major Depressive Disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has...

Aug 03, 2015, 13:32 ET

Par Pharmaceutical Announces Second Quarter 2015 Conference Call

Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, August 7, 2015 at 9:00 a.m. EDT to review its...

Aug 03, 2015, 11:00 ET

FDA Approves The First 3D Printed Drug Product

 Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for...

Jul 30, 2015, 10:21 ET

Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the study to fulfill the post-marketing commitment and...

Jul 30, 2015, 02:00 ET

Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1%

Guidance for FY2015 confirmed, including Core Earnings and Core EPS   Highlights of Q1 results ...